Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | RAC1 | P63000 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30270587 | 0.89 | CYP1A2 (0.58) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL25921866 | 0.89 | CYP1A2 (0.58) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL25933314 | 0.88 | MEN1 (0.58) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL25920636 | 0.81 | MAPT (0.60) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL24125084 | 0.78 | MAPT (0.61) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL25922344 | 0.78 | CYP1A2 (0.56) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL25921173 | 0.78 | MAPT (0.53) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL24124884 | 0.77 | MAPT (0.64) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL24124800 | 0.77 | MAPT (0.62) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL25921176 | 0.77 | CNR2 (0.52) | MEN1KMT2AMAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | MEN1 2558/4885KMT2A 578/4885MAPT 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.